Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Tuberculosis

  Free Subscription


05.07.2021

1 Am J Epidemiol
3 Antimicrob Agents Chemother
1 BMJ
6 Clin Infect Dis
5 Eur Respir J
3 J Immunol
6 PLoS One
2 Trop Med Int Health


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Epidemiol

  1. CAMPBELL JR, Schwartzman K
    The Role of Tuberculosis Screening Among Migrants to Low-Incidence Settings in (Not) Achieving Elimination.
    Am J Epidemiol. 2021 Jul 3. pii: 6313421. doi: 10.1093.
    PubMed         Abstract available


    Antimicrob Agents Chemother

  2. WERNGREN J, Mansjo M, Glader M, Hoffner S, et al
    Detection of pyrazinamide heteroresistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Jun 28:AAC0072021. doi: 10.1128/AAC.00720.
    PubMed         Abstract available

  3. LEY SD, Pillay S, Streicher EM, van der Heijden YF, et al
    Melting the Eis: non-detection of kanamycin resistance markers by routine diagnostic tests and identification of new eis-promoter variants.
    Antimicrob Agents Chemother. 2021 Apr 26. pii: AAC.02502.
    PubMed         Abstract available

  4. SUNDELL J, Wijk M, Bienvenu E, Abelo A, et al
    Factors affecting the pharmacokinetics of pyrazinamide and its metabolites in patients co-infected with HIV - implications for individualized dosing.
    Antimicrob Agents Chemother. 2021 Apr 19. pii: AAC.00046.
    PubMed         Abstract available


    BMJ

  5. NATHAVITHARANA RR, Jijon DF, Pal P, Rane S, et al
    Diagnosing active tuberculosis in primary care.
    BMJ. 2021;374:n1590.
    PubMed        


    Clin Infect Dis

  6. MALIK AA, Becerra MC, Lash TL, Cranmer LM, et al
    Risk Factors for Adverse Events in Household Contacts Prescribed Preventive Treatment for Drug-resistant Tuberculosis Exposure.
    Clin Infect Dis. 2021;72:1709-1715.
    PubMed         Abstract available

  7. HERMANS SM, Zinyakatira N, Caldwell J, Cobelens FGJ, et al
    High rates of recurrent TB disease: a population-level cohort study.
    Clin Infect Dis. 2020 Apr 25. pii: 5825249. doi: 10.1093.
    PubMed         Abstract available

  8. LEE H, Myung W, Lee EM, Kim H, et al
    Mortality and Prognostic Factors of Nontuberculous Mycobacterial Infection in Korea: A Population-based Comparative Study.
    Clin Infect Dis. 2021;72:e610-e619.
    PubMed         Abstract available

  9. CHU AL, Murray MB, Huang CC
    Potential role of latent tuberculosis infection in the pathophysiology of cardiovascular disease.
    Clin Infect Dis. 2021 Jun 28. pii: 6310818. doi: 10.1093.
    PubMed        

  10. BAIK Y, Hanrahan CF, Mmolawa L, Nonyane BAS, et al
    Conditional cash transfers to incentivize tuberculosis screening: Description of a novel strategy for contact investigation in rural South Africa.
    Clin Infect Dis. 2021 Jul 2. pii: 6312933. doi: 10.1093.
    PubMed         Abstract available

  11. PEETLUK LS, Rebeiro PF, Ridolfi FM, Andrade BB, et al
    A clinical prediction model for unsuccessful pulmonary tuberculosis treatment outcomes.
    Clin Infect Dis. 2021 Jul 2. pii: 6313211. doi: 10.1093.
    PubMed         Abstract available


    Eur Respir J

  12. RADTKE KK, Hibma JE, Hesseling AC, Savic RM, et al
    Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children.
    Eur Respir J. 2021;57.
    PubMed        

  13. SOULEYMANE MB, Piubello A, Lawan IM, Hassane-Harouna S, et al
    High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss.
    Eur Respir J. 2021;57.
    PubMed         Abstract available

  14. KOHLI M, MacLean E, Pai M, Schumacher SG, et al
    Diagnostic accuracy of centralised assays for TB detection and detection of resistance to rifampicin and isoniazid: a systematic review and meta-analysis.
    Eur Respir J. 2021;57.
    PubMed         Abstract available

  15. JOUET A, Gaudin C, Badalato N, Allix-Beguec C, et al
    Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs.
    Eur Respir J. 2021;57.
    PubMed         Abstract available

  16. ALAGNA R, Cabibbe AM, Miotto P, Saluzzo F, et al
    Is the new WHO definition of extensively drug-resistant tuberculosis easy to apply in practice?
    Eur Respir J. 2021;58.
    PubMed        


    J Immunol

  17. TIPPALAGAMA R, Singhania A, Dubelko P, Lindestam Arlehamn CS, et al
    HLA-DR Marks Recently Divided Antigen-Specific Effector CD4 T Cells in Active Tuberculosis Patients.
    J Immunol. 2021 Jun 30. pii: jimmunol.2100011. doi: 10.4049/jimmunol.2100011.
    PubMed         Abstract available

  18. NAQVI KF, Huante MB, Saito TB, Endsley MA, et al
    Novel Role for Macrophage Galactose-Type Lectin-1 to Regulate Innate Immunity against Mycobacterium tuberculosis.
    J Immunol. 2021 Jun 28. pii: jimmunol.2001276. doi: 10.4049/jimmunol.2001276.
    PubMed         Abstract available

  19. LI X, Wang M, Ming S, Liang Z, et al
    TARM-1 Is Critical for Macrophage Activation and Th1 Response in Mycobacterium tuberculosis Infection.
    J Immunol. 2021 Jun 28. pii: jimmunol.2001037. doi: 10.4049/jimmunol.2001037.
    PubMed         Abstract available


    PLoS One

  20. DAWIT Z, Abebe S, Dessu S, Mesele M, et al
    Incidence and predictors of mortality among children co-infected with tuberculosis and human immunodeficiency virus at public hospitals in Southern Ethiopia.
    PLoS One. 2021;16:e0253449.
    PubMed         Abstract available

  21. OBSA MS, Daga WB, Wosene NG, Gebremedhin TD, et al
    Treatment seeking delay and associated factors among tuberculosis patients attending health facility in Ethiopia from 2000 to 2020: A systematic review and meta analysis.
    PLoS One. 2021;16:e0253746.
    PubMed         Abstract available

  22. ALMAW G, Conlan AJK, Ameni G, Gumi B, et al
    The variable prevalence of bovine tuberculosis among dairy herds in Central Ethiopia provides opportunities for targeted intervention.
    PLoS One. 2021;16:e0254091.
    PubMed         Abstract available

  23. OUDGHIRI A, Momen G, Aainouss A, Laglaoui A, et al
    Genotypic diversity of multi- and pre-extremely drug-resistant Mycobacterium tuberculosis isolates from Morocco.
    PLoS One. 2021;16:e0253826.
    PubMed         Abstract available

  24. LAZZARI TK, Cavalheiro E, Coutinho SE, da Silva LF, et al
    Leptin and advanced glycation end products receptor (RAGE) in tuberculosis patients.
    PLoS One. 2021;16:e0254198.
    PubMed         Abstract available

  25. ALEMU A, Bitew ZW, Worku T, Gamtesa DF, et al
    Predictors of mortality in patients with drug-resistant tuberculosis: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0253848.
    PubMed         Abstract available


    Trop Med Int Health

  26. TIMIRE C, Ngwenya M, Chirenda J, Metcalfe JZ, et al
    Catastrophic costs among tuberculosis affected households in Zimbabwe: a national health facility-based survey.
    Trop Med Int Health. 2021 Jun 30. doi: 10.1111/tmi.13647.
    PubMed         Abstract available

  27. YADAV J, John D, Allarakha S, Menon GR, et al
    Rising healthcare expenditure on tuberculosis in India: Can India achieve the End-Tb goal?
    Trop Med Int Health. 2021 Jun 30. doi: 10.1111/tmi.13648.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: